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The development of molecularly targeted drugs has greatly advanced cancer therapy, despite these drugs being associated with
some serious problems. Recently, increasing attention has been paid to the anticancer eﬀects of natural products. α-Mangostin,
a xanthone isolated from the pericarp of mangosteen fruit, has been shown to induce apoptosis in various cancer cell lines and
to exhibit antitumor activity in a mouse mammary cancer model. In this study, we investigated the inﬂuence of α-mangostin
on apoptosis and cell cycle in the human breast cancer cell line MDA-MB231 (carrying a p53 mutation, and HER2, ER, and
PgR negative) in order to elucidate its anticancer mechanisms. In α-mangostin-treated cells, induction of mitochondria-mediated
apoptosis was observed. On cell-cycle analysis, G1-phase arrest, increased p21cip1 expression and decreases in cyclins, cdc(s), CDKs
and PCNA were observed. In conclusion, α-mangostin may be useful as a therapeutic agent for breast cancer carrying a p53
mutation and having HER2- and hormone receptor-negative subtypes.
1.Introduction
Various molecularly targeted drugs against a range of
cancers, including breast cancer, have recently been devel-
oped. Trastuzumab is a monoclonal antibody against
human epidermal growth factor (HER/ErbB) receptor 2
(HER2/ErbB2). Around 15–20% of patients with breast
cancer have HER2-positive tumors, and overexpression of
HER2 is observed in these patients [1]. Trastuzumab has
been shown to induce tumor regression in such patients.
Sunitinib, sorafenib, and bevacizumab are multitargeted
tyrosine kinase inhibitors that inhibit tumor neovascular-
ization and are currently in clinical trials [2, 3]. These
drugs are associated with serious problems such as adverse
eﬀects, drug resistance, and low eﬃcacy of single therapy,
particularly against metastatic or recurrent breast cancer.
Hormone therapy has also been used against hormone
receptor-positive breast cancer. However, about 10 to 15% of
breast cancers do not express either estrogen or progesterone
receptor (ER and PgR, resp.) and do not overexpress the
HER2 gene [4].
Mangosteen (Garcinia mangostana Linn) pericarp con-
tains various phytochemicals, primarily xanthones, and the
resin extracts have long been used for medicinal purposes
in Southeast Asia [5]. α-Mangostin is a one of xanthones
present in mangosteen pericarp (78% content). A recent
study has shown that α-mangostin induces cell-cycle arrest
and apoptosis in various types of human cancer cells [5–
8]. We previously reported that α-mangostin signiﬁcantly
inhibits both tumor growth and metastasis in a mouse
model of mammary cancer [9, 10]. In addition, α-mangostin
treatment signiﬁcantly decreased the levels of phospho-Akt-
threonine 308(Thr308) in a human mammary carcinoma
cell line and mammary carcinoma tissues in vivo [10].2 Journal of Biomedicine and Biotechnology
Here, we investigated the antitumor potential of α-
m a n g o s t i no na p o p t o s i sa n dc e l lc y c l ea r r e s ti nah u m a n
breast cancer cell line carrying a p53 mutation and having
HER2-, ER-, and PgR-negative status.
2.MaterialsandMethods
2.1. Experimental Regimen. Mangosteen (Garcinia man-
gostana Linn) pericarps were dried, ground, and successively
extracted in water and 50% ethanol. After freeze-drying
the 50% ethanol extract, the resultant dried powder was
suspended in water partitioned with ethyl acetate. The
ethyl acetate extract was then puriﬁed by chromatography
on silica gel with the n-hexane-ethyl acetate system and
recrystallized to give α-mangostin at >98% purity. For in
vitro use, crystallized α-mangostin was dissolved in dimethyl
sulphoxide (DMSO), and aliquots of stock 20mM solution
were stored at −20◦C.
2.2. Cell Line. The MDA-MB231, a human mammary
carcinoma cell line stably expressing the green ﬂuores-
cence protein (GFP) [11], was maintained in RPMI-1640
medium containing 10% fetal bovine serum with strep-
tomycin/penicillin in an incubator under 5% CO2.M D A -
M B 2 3 1c e l l sh a v eap 5 3m u t a t i o n[ 12, 13] and HER2-, ER-,
and PgR, negative feature [14].
2.3. Cell Viability. MDA-MB231 cells were grown in RPMI-
1640 medium supplemented with 10% bovine serum under
an atmosphere of 95% air and 5% CO2 at 37◦C. These
cells were plated into 96-well plates (1 × 104 cells/well)
one day before α-mangostin treatment. They were subse-
quently incubated for 24h with culture medium containing
DMSO vehicle alone (control) or with medium containing
α-mangostin at various concentrations up to 48μM. Cell
viability was determined using a Cell-Titer-Bule Cell Via-
bility Assay (Promega Co., Madison, WI, USA). The IC50
under these conditions was found to be 20μM α-mangostin
for 24h treated and 16μM for 48h treated in MDA-MB231
cells; thus, all in vitro studies were performed using 20μM
α-mangostin.
2.4. Time-Lapse Imaging. Cells were grown on 35mm cul-
ture dishes under the above-mentioned condition. These
cells were subsequently incubated for 24h with culture
medium containing DMSO vehicle alone (control) or with
mediumcontaining20μMα-mangostin.Imaginghasstarted
when the reagents were added into dishes. Time-lapse
imagesweretakenusingtheﬂuorescencemicroscopeBZ8000
( K e y e n c e ,O s a k a ,J a p a n ) .
2.5. Nuclear Staining. For nuclear staining, DAPI with
mounting medium (Vector Laboratories, Inc., Burlingame,
CA, USA) was used after immunoﬂuorescence staining.
For morphological examination of apoptotic changes,
Hoechst33342 (Lonza Walkersville, Inc., Walkersville, MD,
USA) was added to cultured medium at a concentration of
5μg/mL.
2.6. Caspase Activity. M D A - M B 2 3 1c e l l sw e r ep l a t e di n t o
96-well plates at a concentration of 1 × 104 cells/well
one day before α-mangostin treatment. Cells were treated
with 20μM α-mangostin or DMSO alone for 24h. The
activities of caspase-3, caspase-8, caspase-9, and caspase-
4 were measured using a Fluorometric Protease Assay Kit
(MBL, Inc., Nagoya, Japan) in which cells were lysed with
Cell Lysis Buﬀer contained in this kit and the protein
concentration adjusted to 50μg in each sample. Caspase
activity was measured in terms of ﬂuorescence intensity
producedbycaspasecleavageofthecorresponding substrate,
using Fluoroskan Ascent (Thermo Election Co., Helsinki,
Finland).
2.7. Cell-Cycle Distribution. Flow cytometric analysis was
conducted on trypsinized MDA-MB231 cell suspensions
that were harvested after a 24h treatment with 20μM
α-mangostin and ﬁxed in cold 70% ethanol. The cells
were stained with a 50μg/mL propidium iodide solution
containing 100μg/mL RNase A for 20min at 37◦C and then
placed on ice just prior to ﬂow cytometric analysis (EPICS
Elite ESP; Coulter Co., Miami, FL, USA). The percentage of
cells in each phase of the cell cycle was determined using a
Multicycle Cell-Cycle Analysis program (Coulter Co.).
2.8. ssDNA Analysis. MDA-MB231 cells were plated into
96-well plates at a concentration of 1 × 104 cells/well one
day before α-mangostin treatment. Cells were treated with
20μM α-mangostin or DMSO alone for 24h. Single-Strand
breakDNA(ssDNA)levelsweredetectedbyusingApoStrand
ELISA Apoptosis Detection Kit (Enzo Life Sciences Interna-
tional, Inc., Butler Pike Plymouth Meeting, PA, USA) and
measured using Microplate reader (Corona ELECTRIC Co.
Ltd., Ibaraki, Japan).
2.9. Cytochrome c Release. Cytochrome c leaving the mito-
chondrial membrane was measured using the InnoCyte Flow
Cytometric Cytochrome c Release Kit (Merck; Darmstadt,
Germany). MDA-MB231 cells were harvested after a 24h
treatment with 20μM α-mangostin or DMSO alone and 1 ×
106 cells were resuspended in 300μL Permeabilization Buﬀer
to remove the cytosolic cytochrome c. The cells were ﬁxed
4% paraformaldehyde and washed. After treatment with
blocking buﬀer, the cells were treated with anticytochrome
c mouse monoclonal antibody (clone 7H8, Santa Cruz,
Biotechnology, CA, USA), followed by secondary antibody
conjugated to FITC. Then, the cells were analyzed using a
ﬂow cytometer, BD FACSAria (Becton Dickinson, Franklin
Lakes, NJ, USA).
2.10. Immunoﬂuorescence Staining. MDA-MB231 cells were
grown on 24mm × 24mm cover glasses and ﬁxed in 4%
formaldehyde solution in phosphate buﬀer. Immunoﬂuores-
cence staining was performed with anti-PCNA mouse mon-
oclonal antibody (clone PC10; Cell Signaling Technology,
Danvers, MA, USA), cyclin D1 rabbit monoclonal antibody
(clone 92G2; Cell Signaling Technology), p21cip1 rabbit
polyclonalantibody(cloneC-19;SantaCruzBiotechnology).
These antibodies were also used in Western blotting.Journal of Biomedicine and Biotechnology 3
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Figure 1: Cell viability and apoptosis detection in MDA-MB231 cells after α-mangostin treatment. (a) Cell viability was signiﬁcantly lower
in human mammary carcinoma MDA-MB231 cells treated with more than 12μM α-mangostin for 24 or 48h (∗P<0.05, ∗∗P<0.01). Five
samples from each of α-mangostin dosage were examined. The IC50 concentration was determined to be 20μM for 24h; therefore, 20μM
α-mangostin was used for all in vitro studies. (b) Morphological changes in MDA-MB231 cells treated with 20μM α-mangostin for 24h,
as compared to controls. Upper two panels show controls and lower two panels show α-mangostin-treated cells. α-Mangostin-treated cells
appeared shrunken and chromatin condensation was observed (yellow arrow heads in lower right panel). Scale bars = 50μm. (c) ssDNA
levels were determined by ELISA and were signiﬁcantly elevated in cells treated with α-mangostin for 24h, as compared to control levels
(∗∗∗P<0.001). Data are presented as mean ± SD. For all analyses, ﬁve samples from control and α-mangostin-treated cells were examined.
2.11. Western Blotting. Total protein was extracted from
whole cell lysates of MDA-MB231 cells treated with DMSO
or α-mangostin according to the IC50 data previously stated.
Total protein (40μg) was fractionated on 16% SDS-PAGE
mini gels (TEFCO, Tokyo, Japan) under reducing condi-
tions and transferred to PVDF membranes (Immobilon -
P Transfer Membrane, Millipore; Billerica, MA, USA). The
membranes were activated in 100% methanol for 15 seconds
and incubated with primary antibodies for the following
proteins: cytochrome c, Bid, PCNA, cyclin D1, p21cip1,a n d
β-actin. Membranes were then incubated with the corre-
sponding secondary antibodies conjugated with horseradish
peroxidase (HRP). β-Actin (clone N-21) and Full-length Bid
(clone FL-195) antibodies were from Santa Cruz Biotech-
nology. Antibody recognizing cleaved Bid was obtained from
R&D Systems (R&D Systems, Inc, Minneapolis, MN, USA).
Antibodybindingwassubsequentlyvisualizedbyexposureto
an enhancing chemiluminescence reagent (Amersham ECL;4 Journal of Biomedicine and Biotechnology
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Figure 2: Caspase activity of MDA-MB231 cells after treatment with α-mangostin. Caspase activity was evaluated by luminescence assay.
Activity of caspase-3, caspase-8, and caspase-9, but not caspase-4, was signiﬁcantly elevated in MDA-MB231 cells treated with 20μM α-
m a n g o s t i nf o r2 4h( ∗∗P<0.01). Data are presented as mean ± SD. Five samples from control and α -mangostin-treated cells were used for
measurement of caspase activity.
GE Healthcare UK Ltd., Buckinghamshire, UK). Blots were
visualized using a LAS-3000 image analyzer (Fujiﬁlm, Co.,
Tokyo, Japan).
2.12. Real-Time PCR. MDA-MB231 cells were treated with
DMSO or 20μM α-mangostin for 6, 12, and 24h. Protein
was extracted using cell lysis buﬀer containing protease and
phosphatase inhibitor cocktail. Total RNA was extracted
from these cells with FastPure RNA kit (Takara Bio Inc.,
Shiga, Japan) and cDNAs were synthesized with PrimeScript
RT reagent kit (Takara Bio Inc.). Primers involved in the
cell-cycle regulation were used containing PrimerArray Cell
cycle (human) (Takara Bio Inc.) and real-time PCR reaction
w a sp e r f o r m e dw i t hT h e r m a lC y c l e rD i c eR e a lT i m e( T a k a r a
Bio Inc.). Data were corrected against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) values and expressed as
mean ± SD.
2.13. Statistical Analysis. Signiﬁcant diﬀerences in the quan-
titative data between groups were analyzed using Student’s t-
testviathemethodofWelch,andP valueslessthan0.05were
considered to represent a statistically signiﬁcant diﬀerence.
3. Results and Discussion
3.1. Cell Viability. Viability analyses of MDA-MB231 human
mammary cancer cells showed signiﬁcantly lower viabilityJournal of Biomedicine and Biotechnology 5
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Figure 3: Cytochrome c expression, Bid cleavage, and cell-cycle distribution of MDA-MB231 cells after α-mangostin treatment. (a)
Cytochrome c in mitochondria, as determined by ﬂow cytometry (black line indicates α-mangostin-treated cells and gray line indicates
controls). The levels of cytochrome c protein in mitochondrial fractions were signiﬁcantly lower in cells treated with α-mangostin for 24h
(b). Western blots of cytochrome c (15kDa) showed signiﬁcant decreases in cells treated with α-mangostin for 24h, as compared to controls
(upper panel). In α-mangostin-treated cells, cytochrome c was released from mitochondria, leading to decreases in concentration. β-Actin
served as an internal control (lower panel, same in (c)). (c) Western blots of Bid (22kDa) in control cells and cells treated with α-mangostin
for 24h were similar (upper panel). Cleaved Bid was not observed after α-mangostin treatment. Three samples were used for all analyses in
(a)–(c). (d) Cell-cycle analysis conﬁrmed that α-mangostin induced arrest in the G1-phase and inhibition of cells entering the S-phase in
MDA-MB231 cells (∗∗P<0.01). Data are presented as mean ± SD of triplicate, independent measurements.
after 24 and 48h of treatment with more than 12μM α-
mangostin (Figure 1(a)). Based on the IC50 data, 20μMw a s
determined to be the optimal concentration of α-mangostin
for in vitro studies.
3.2.MorphologicalChanges. Formorphologicalexamination
of apoptotic changes, MDA-MB231 cells were stained with
Hoechst 33342 (Figure 1(b)). After 20μM α-mangostin
treatment for 24h, cells appeared shrunken and chromatin
condensation was observed (yellow arrow heads in lower
right panel). These changes suggest that the antiproliferative
eﬀectsofα-mangostinareassociatedwithapoptosisinMDA-
MB231 human mammary cancer cells. Furthermore, we
performed time-lapse imaging from the start of 20μM α-
mangostin treatment for 24h. After 6h, cell proliferation
started to decrease signiﬁcantly and cell shape had changed
after 12h (data not shown).
3.3. Apoptosis Studies
3.3.1. ssDNA Analysis. In order to conﬁrm that the mor-
phological changes observed after α-mangostin treatment
occurred as a consequence of apoptosis, we measured ssDNA
levels of α-mangostin treated cells, as compared to controls.
In α-mangostin-treated cells, ssDNA levels were signiﬁcantly
elevated (P<0.001, Figure 1(c)). This suggests that the6 Journal of Biomedicine and Biotechnology
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Figure 4: Real-time PCR analysis of gene expression associated with cell cycle. mRNA expression of cell-cycle-related genes, such as cyclins,
cdc(s), CDKs, and PCNA, was examined by real-time PCR assay in MDA-MB231 cells after treatment with α-mangostin, as compared
with controls. White bars and gray bars show the results of analysis for 6h and 12h after treatment with 20μM α-mangostin, respectively
(∗P<0.05, ∗∗P<0.01). Relative levels of target gene expression were calculated using the ΔΔ CT method. GAPDH was used as a reference
gene. Data are presented as means ± SD of triplicate independent measurements.
morphological changes in human mammary cancer cells
that occurred after α-mangostin treatment were caused by
apoptosis.
3.3.2. Caspase Activity. Signiﬁcantly elevated caspase-3, cas-
pase-8, and caspase-9 activity was observed in MDA-MB231
cells treated with α-mangostin for 24h (Figure 2), as com-
pared to controls. The activity of caspase-4 did not diﬀer
signiﬁcantly between control cells and α-mangostin-treated
cells (Figure 2). These results indicate that α-mangostin-
induced mitochondria mediated apoptosis.
3.3.3. Cytochrome c Release. I no r d e rt oc o n ﬁ r mm i t o c h o n -
dria-mediated apoptosis, levels of cytochrome c were mea-
sured by ﬂow cytometry and Western blot. The levels
of cytochrome c protein in mitochondrial fractions were
signiﬁcantly lower in cells treated with α-mangostin for
24h (Figure 3(a)). Cytochrome c protein was released
from mitochondria, leading to decreases in concentration
(Figure 3(b)). These results were strongly suggesting engage-
ment of the mitochondria-mediated apoptotic pathway.
3.3.4. Bid Cleavage. As caspase-8 activity was elevated, we
examined whether the mitochondrial pathway was activated
via caspase-8-Bid cleavage by performing Western blots
for Bid. Full-length Bid (22kDa) was equally detected in
control cells and in cells treated with α-mangostin for 24h
(Figure 3(c)); this indicates that no Bid cleavage occurred.
In addition, no cleaved Bid (15kDa) was observed when
using cleaved Bid-detectable antibody in any of the groups
(data not shown). These results suggest that apoptosis
was induced by α-mangostin via mitochondria, but was
not accompanied by Bid cleavage. We previously reported
that α-mangostin decreased phospho-Akt-Th308 in MDA-
MB231 cells and mammary carcinoma tissues [10]. Akt
is a serine/threonine protein kinase that mediates the
downstream eﬀects of phosphatidylinositol 3-kinase (PI3K)
by phosphorylating multiple targets involved in regulating
diverse cellular functions, including proliferation, growth,
and survival. Therefore, Akt phosphorylation by therapeutic
agents leads to growth inhibition, cell-cycle arrest, and
apoptosis in cancer cells. A previous study in human colon
cancer cells showed that α-mangostin inhibited Erk1/2Journal of Biomedicine and Biotechnology 7
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and Erk5 phosphorylation involving the mitogen-activated
protein kinase (MAPK) signaling pathway [5]. PI3K/Akt
and Erk signaling target Bcl-2-associated agonists of cell
death (Bad), a member of the Bcl-2 family. Bcl-2 family
members are known to be regulators of programmed cell
death. Bad promotes apoptosis by displacing Bax, another
Bcl-2 family member, from binding to Bcl-2 and Bcl-xL,
causing cytochrome c release from mitochondria [15]. These
data suggest that apoptotic cell death caused by α-mangostin
treatment in human mammary carcinoma cells occurs via
mitochondria-mediated apoptosis, followed by inhibition of
PI3K/Aktsignalingpathway,andmayincludeBadactivation.
3.4. Cell-Cycle Distribution. As measured by ﬂow cytometry,
24h exposure to 20μM α-mangostin induced a signiﬁcant
elevationinthenumberofcellsintheG1-phase,ascompared
with control cells (Figure 3(d)). There was also a signiﬁcant
reduction in the S-phase population in α-mangostin-treated
cells (Figure 3(d)). These results suggest that G1-phase arrest
was the result of α-mangostin inhibiting entry into S-phase.
3.5. Expression of Cell-Cycle Regulatory Genes. As α-man-
gostintreatmentinducedcell-cyclearrest,weinvestigatedthe
expression of cell-cycle regulatory genes. Real-time analysis
revealed that the expression of p21cip1 was up-regulated and
CHEK2 expression tended to increase for more than 6h
after α-mangostin treatment (Figure 4). p21cip1 is a cyclin-
dependent kinase inhibitor and the encoded protein binds
to and inhibits the activity of cyclin-CDK2 (CDK: cyclin-
dependentkinase)or-CDK4complexes,therebyfunctioning8 Journal of Biomedicine and Biotechnology
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Figure 6: Expression of PCNA, cyclin D1 and p21cip1 proteins after α-mangostin treatment. Immunoﬂuorescence of PCNA (a)–(f), cyclin
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as a regulator of cell-cycle progression at the G1-phase
[16]. CHEK2 is one of the cell-cycle checkpoint regulators
and putative tumor suppressors that lead to G1-phase
arrest through CDK phosphatase and cell division cycle
25 homolog A (cdc25A) phosphorylation [17]. Increases
in p21cip1 and CHEK2 expression lead to decreases in
CDKs and cyclins, and G1-phase arrest and inhibition of
cell proliferation, followed by decreases in proliferating
cell nuclear antigen (PCNA). Furthermore, we conﬁrmed
the expression of G1/S-phase-related molecules, particularly
p21cip1, PCNA, and cyclin D1 by using Western blotting and
immunoﬂuorescence staining (Figures 5 and 6). On Western
blotting analysis, PCNA (36kDa) and cyclin D1 (36kDa)
protein weresigniﬁcantly lower, and p21cip1 (21kDa) protein
was signiﬁcantly elevated in cells treated with α-mangostin
for 24h, as compared to controls (Figure 5(d)). These results
agreed with those of the real-time PCR analysis shown
in Figures 4 and 5(a)–5(c). Immunoﬂuorescence stainingJournal of Biomedicine and Biotechnology 9
revealed that PCNA and cyclin D1 expression were lower
and that p21cip1 expression was elevated in the nuclei of α-
mangostin-treated cells, as compared to controls (Figure 6).
These results suggest that α-mangostin induces G1-phase
arrest and S-phase suppression by altering the expression of
cell-cycle-related molecules, such as p21cip1, CHEK2, cyclins,
cdc(s), CDKs, and PCNA.
4. Conclusion
In conclusion, our results demonstrated that the therapeutic
eﬀects of α-mangostin are mediated by mitochondria-
mediated apoptosis under control of the PI3K/Akt signaling
pathway. α-Mangostin may be useful as a therapeutic agent
for breast cancer carrying a p53 mutation and including
HER2/hormone-negative subtypes.
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